Cmpd10357 to treat B-cell acute lymphoblastic leukemia

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• B-cell acute lymphoblastic leukemia (B-ALL) is a common childhood cancer with high relapse rates.
• Existing treatments have limitations, necessitating novel therapeutic approaches.
• Cmpd10357 has demonstrated efficacy against solid tumors.

Purpose of the Study:

• To evaluate the efficacy of Cmpd10357 against B-cell acute lymphoblastic leukemia (B-ALL).
• To elucidate the mechanism of Cmpd10357-induced cytotoxicity in B-ALL cells.

Main Methods:

• Cytotoxicity assays were performed on B-ALL cell lines (JM1 and Reh).
• In vivo efficacy was assessed using a B-ALL xenograft mouse model.
• Mechanism of cell death was investigated, including apoptosis and necrosis pathways.

Main Results:

• Cmpd10357 exhibited concentration-dependent cytotoxicity in B-ALL cell lines (IC50 values of 3.2 and 3.3 μM).
• Cmpd10357 significantly prolonged survival in a B-ALL xenograft mouse model.
• Cytotoxicity was mediated by caspase-independent necrosis, involving apoptosis-inducing factor (AIF) nuclear translocation and inhibited by Necrostatin-1.

Conclusions:

• Cmpd10357 demonstrates potent anti-leukemic activity against B-ALL.
• The compound induces cancer cell death through a novel AIF-mediated necrosis pathway.
• Cmpd10357 represents a promising therapeutic candidate for B-ALL, potentially for combination therapies.